Abstract

Circulating tumor cells (CTCs) in the blood of cancer patients are of high clinical relevance. Since detection and isolation of CTCs often rely on cell dimensions, knowledge of their size is key. We analyzed the median CTC size in a large cohort of breast (BC), prostate (PC), colorectal (CRC), and bladder (BLC) cancer patients. Images of patient-derived CTCs acquired on cartridges of the FDA-cleared CellSearch® method were retrospectively collected and automatically re-analyzed using the accept software package. The median CTC diameter (μm) was computed per tumor type. The size differences between the different tumor types and references (tumor cell lines and leukocytes) were nonparametrically tested. A total of 1962 CellSearch® cartridges containing 71612 CTCs were included. In BC, the median computed diameter (CD) of patient-derived CTCs was 12.4μm vs 18.4μm for cultured cell line cells. For PC, CDs were 10.3μm for CTCs vs 20.7μm for cultured cell line cells. CDs for CTCs of CRC and BLC were 7.5μm and 8.6μm, respectively. Finally, leukocytes were 9.4μm. CTC size differed statistically significantly between the four tumor types and between CTCs and the reference data. CTC size differences between tumor types are striking and CTCs are smaller than cell line tumor cells, whose size is often used as reference when developing CTC analysis methods. Based on our data, we suggest that the size of CTCs matters and should be kept in mind when designing and optimizing size-based isolation methods.

Highlights

  • Circulating tumor cells (CTCs) are disseminated from solid malignancies and present in the peripheral circulation of patients of multiple tumor types [1]

  • Assessment of the original CellSearchÒ CTC counts showed that for breast cancer (BC), a total of 48 242 blood-derived (CTC-B) and 3285 CTCs derived from cerebrospinal fluid [circulating tumor cells derived from cerebrospinal fluid (CTC-L)(iquor)]

  • We assessed the median size of CTCs in a large cohort of BC, prostate cancer (PC), CRC, and bladder cancer (BLC) patients using Automated CTC Classification (ACCEPT) hypothesizing that there might be a difference in CTCs across tumor types and between patient-derived CTCs and cell line cells, implying the need for tumor-specific CTC isolation methods

Read more

Summary

Introduction

Circulating tumor cells (CTCs) are disseminated from solid malignancies and present in the peripheral circulation of patients of multiple tumor types [1]. They are thought to originate from all tumor lesions present in the body. CTCs could reflect a sample of the molecular landscape of the disease in real time when successfully captured and characterized. Molecular Oncology 15 (2021) 116–125 a 2020 The Authors.

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.